Maintenance immunosuppression in myasthenia gravis, an update

Area of Science:

• Neurology
• Immunology

Background:

• Myasthenia gravis (MG) is an autoimmune disorder affecting neuromuscular junctions.
• Treatment involves symptomatic management and immunosuppression/immunomodulation.

Purpose of the Study:

• To critically review the practical aspects of long-term immunosuppressive therapy in MG.
• To guide the application of specific therapies based on efficacy, safety, and patient factors.

Main Methods:

• Literature review of current immunosuppressive and immunomodulatory treatments for MG.
• Analysis of factors influencing treatment selection, including efficacy, adverse effects, disease characteristics, and comorbidities.

Main Results:

• A wide range of immunosuppressive options exist for MG, including corticosteroids, azathioprine, mycophenolate mofetil, and biologics like rituximab and eculizumab.
• Treatment selection is individualized based on disease severity, subtype, patient comorbidities, and the known risk-benefit profiles of each therapy.

Conclusions:

• Effective long-term management of myasthenia gravis requires a personalized approach to immunosuppressive therapy.
• Careful consideration of treatment efficacy, safety profiles, and individual patient characteristics is crucial for optimizing outcomes in MG patients.